WHO ICTRP trial
Sertraline effectiveness in prevention of depression in MS patients.
IRCT2015090723927N1 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT2015090723927N1 |
|---|---|
| Public title | Sertraline effectiveness in prevention of depression in MS patients. |
| Scientific title | Sertraline effectiveness in prevention of depression, fatigue reduction and QOL improvement in MS patients. |
| Primary sponsor | Vice chancellor for research,Tabriz university of medical science. |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 2-3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Multiple sclerosis. Multiple sclerosis;Multiple sclerosis |
| Interventions | Intervention 1: In study group we will add 50 mg sertraline produced by sobhan manufacture every day for six months,this group will consider at the beginning ,end of 1th month, 3th month and end 6th month for depression symptoms… |
| Registration date | Nov 2, 2015 |
| Target size | 60 |
| Secondary IDs | --------;-------- |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: